Cargando…
Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Anti-angiogenic therapies were approved for different cancers. However, significant primary and secondary resistance hampers efficacy in several tumor types including breast cancer. Thus, we need to develop clinically applicable strategies to enhance efficacy of anti-angiogenic drugs. We report that...
Autores principales: | Ben-Batalla, Isabel, Cubas-Cordova, Miguel, Udonta, Florian, Wroblewski, Mark, Waizenegger, Jonas S., Janning, Melanie, Sawall, Stefanie, Gensch, Victoria, Zhao, Lin, Martinez-Zubiaurre, Iñigo, Riecken, Kristoffer, Fehse, Boris, Pantel, Klaus, Bokemeyer, Carsten, Loges, Sonja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467441/ https://www.ncbi.nlm.nih.gov/pubmed/25849942 |
Ejemplares similares
-
Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
por: Wroblewski, M., et al.
Publicado: (2017) -
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
por: Beitzen-Heineke, Antonia, et al.
Publicado: (2021) -
Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
por: Schieferdecker, Aneta, et al.
Publicado: (2014) -
BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
por: Wroblewski, Mark, et al.
Publicado: (2018) -
Regulation of bone homeostasis by MERTK and TYRO3
por: Engelmann, Janik, et al.
Publicado: (2022)